2,3-dimethyl-5-nitrobenzoic acid | 110969-50-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,3-dimethyl-5-nitrobenzoic acid
• 英文别名: 2,3-Dimethyl-5-nitro-benzoesaeure
• CAS: 110969-50-1
• 化学式: C₉H₉NO₄
• 分子量: 195.175
• InChiKey: LAUMVOSQJSQRJG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  83.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2,3-dimethyl-5-nitrobenzoic acid 在 氯化亚砜 、 N,N-二甲基甲酰胺 作用下， 以 氯苯 为溶剂， 反应 4.0h， 以70%的产率得到chlorure de dimethyl-2,3 nitro-5 benzoyle
  参考文献：
  名称：

  Maguer, Pierre, Bulletin de la Societe Chimique de France, 1987, # 1, p. 199 - 204

  摘要：

  DOI：
• 作为产物：
  描述：

  2,3-dimethyl-5-nitrobenzonitrile 在 磷酸 作用下， 生成 2,3-dimethyl-5-nitrobenzoic acid
  参考文献：
  名称：

  REACTION OF ANHYDROSEPEDONIN WITH ALKALI SYNTHESIS OF A DEGRADATION PRODUCT AND SOME RELATED DIMETHYLHYDROXYBENZOIC ACIDS

  摘要：

  从无水石蕈酮与碱反应中分离出两种产物，并鉴定为3-羟基-5-甲基苯甲酸和3,4-二甲基-5-羟基苯甲酸。后一化合物的结构通过明确的合成得到确认。在这项工作中，还制备了从o-二甲苯衍生的其余o-和m-羟基苯甲酸。

  DOI：

  10.1139/v64-010

文献信息

• COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY
  申请人：Li Hui

  公开号：US20120028923A1

  公开（公告）日：2012-02-02

  Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful. Also disclosed are methods of making the compounds.

  披露了公式I的化合物，含有它们的组合物，以及使用这些化合物和组合物治疗调节JAK途径或抑制JAK激酶，特别是JAK2和JAK3，具有治疗用途的条件的方法。还披露了制造这些化合物的方法。
• [EN] ISOINDOLINONE COMPOUNDS<br/>[FR] COMPOSÉS D'ISO-INDOLINONE
  申请人：MONTE ROSA THERAPEUTICS

  公开号：WO2021069705A1

  公开（公告）日：2021-04-15

  Disclosed herein is a compound or pharmaceutically acceptable salts or stereoisomers thereof of of formula I wherein X1 is linear or branched C1-6 alkyl, C3-6 cycloalkyl, -C1-6 alkyl C3-6 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C1-6 alkyl C6-10 aryl, C1-6 alkyl 5-10 membered heteroaryl, wherein X1 is unsubstituted or substituted with one or more of halogen, linear or branched C1-6 alkyl, linear or branched C1-6 heteroalkyl, CF3, CHF2, -O-CHF2, -O-(CH2)2-OMe, OCF3, C1-6 alkylamino, -CN, -N(H)C(O)-C1- 6alkyl, -OC(O)-C1-6alkyl, -OC(O)-C1-4alkylamino, -C(O)O-C1-6alkyl, -COOH, - CHO, -C1-6alkylC(O)OH, -C1-6alkylC(O)O-C1-6alkyl, NH2, C1-6 alkoxy or C1-6 alkylhydroxy; X2 is hydrogen, C6-10 aryl, 5-10 membered heteroaryl, -O-(5-10 membered heteroaryl), 4-8 membered heterocycloalkyl, C1-4 alkyl 4-8 membered heterocycloalkyl, -O-(4-8 membered heterocycloalkyl), -O-C1-4 alkyl-(4-8 membered heterocycloalkyl), -OC(O)-C1-4alkyl-4-8 membered heterocycloalkyl or C6 aryloxy, wherein X2 is unsubstituted or substituted with one or more of linear or branched C1-6 alkyl, NH2, NMe2 or 5-6 membered heterocycloalkyl; n is 0, 1 or 2.

  本公开涉及一种化合物或药用可接受盐或其立体异构体，其化学式为I，其中X1为直链或支链的C1-6烷基，C3-6环烷基，-C1-6烷基C3-6环烷基，C6-10芳基，5-10成员杂芳基，C1-6烷基C6-10芳基，C1-6烷基5-10成员杂芳基，其中X1未取代或取代为一个或多个卤素，直链或支链的C1-6烷基，直链或支链的C1-6杂烷基，CF3，CHF2，-O-CHF2，-O-(CH2)2-OMe，OCF3，C1-6烷基氨基，-CN，-N(H)C(O)-C1-6烷基，-OC(O)-C1-6烷基，-OC(O)-C1-4烷基氨基，-C(O)O-C1-6烷基，-COOH，-CHO，-C1-6烷基C(O)OH，-C1-6烷基C(O)O-C1-6烷基，NH2，C1-6烷氧基或C1-6烷基羟基；X2为氢，C6-10芳基，5-10成员杂芳基，-O-(5-10成员杂芳基)，4-8成员杂环烷基，C1-4烷基4-8成员杂环烷基，-O-(4-8成员杂环烷基)，-O-C1-4烷基-(4-8成员杂环烷基)，-OC(O)-C1-4烷基-4-8成员杂环烷基或C6芳氧基，其中X2未取代或取代为一个或多个直链或支链的C1-6烷基，NH2，NMe2或5-6成员杂环烷基；n为0、1或2。
• Indole derivatives
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US05283251A1

  公开（公告）日：1994-02-01

  Indole derivatives of the following formula: ##STR1## wherein R.sup.1 is carboxy(lower)alkyl or protected carboxy(lower)alkyl, R.sup.2 is hydrogen, lower alkyl or halogen, R.sup.3 and R.sup.4 are each hydrogen or lower alkyl, R.sup.5 is ar(lower)alkyl which may have suitable substituent(s), and A is carbonyl, sulfonyl or lower alkylene, or a pharmaceutically acceptable salt thereof, which are useful as a testosterone 5.alpha.-reductase inhibitor.

  以下化学式的吲哚衍生物：##STR1## 其中 R.sup.1 是羧基(较低)烷基或保护羧基(较低)烷基，R.sup.2 是氢、较低烷基或卤素，R.sup.3 和 R.sup.4 各自是氢或较低烷基，R.sup.5 是可能具有适当取代基的芳基(较低)烷基，A 是羰基、磺酰基或较低烷基，或其药用可接受盐，可用作睾酮5α-还原酶抑制剂。
• Discovery of N-(3-(morpholinomethyl)-phenyl)-amides as potent and selective CB2 agonists
  作者：Karin Worm、Damian G. Weaver、Rosalyn C. Green、Christopher T. Saeui、Doreen-Marie S. Dulay、William M. Barker、Joel A. Cassel、Gabriel J. Stabley、Robert N. DeHaven、Christopher J. LaBuda、Michael Koblish、Bernice L. Brogdon、Steven A. Smith、Roland E. Dolle

  DOI：10.1016/j.bmcl.2009.07.057

  日期：2009.9

  benzamides were identified as a novel series of cannabinoid receptor ligands. Replacing the sulfonamide functionality and reversing the original carboxamide bond led to the discovery of N-(3-(morpholinomethyl)-phenyl)-amides as potent and selective CB2 agonists. Selective CB2 agonist 31 (Ki = 2.7; CB1/CB2 = 190) displayed robust activity in a rodent model of postoperative pain.

  最近，氨磺酰基苯甲酰胺被确定为一系列新的大麻素受体配体。取代磺酰胺官能团并逆转原始的羧酰胺键导致发现N-（3-（吗啉代甲基）-苯基）-酰胺作为有效的和选择性的CB 2激动剂。选择性CB 2激动剂31（K i  = 2.7； CB 1 / CB 2  = 190）在术后疼痛的啮齿动物模型中显示出强大的活性。
• Organic Compounds
  申请人：Ehara Takeru

  公开号：US20090192148A1

  公开（公告）日：2009-07-30

  The invention relates to 3,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,5-substituted piperidine compound, a method for the manufacture of a 3,5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. The compounds have the formula I′ wherein R1, R2, T, R3 and R4 areas defined in the specification.

  本发明涉及3,5-取代哌啶化合物，这些化合物用于诊断和治疗温血动物，特别是用于治疗依赖肾素活性的疾病（=失调）；该类化合物用于制备治疗依赖肾素活性疾病的制剂；该类化合物用于治疗依赖肾素活性的疾病；包括3,5-取代哌啶化合物的制药配方和/或包括给予3,5-取代哌啶化合物的治疗方法，以及制造3,5-取代哌啶化合物的新型中间体和部分合成步骤。该化合物的式子为I'，其中R1、R2、T、R3和R4在规范中有定义。